Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| Tahke dispersioon (Solid Dispersion Formulation)× | Caco-2 rakukultuuri läbilaskvuse test× | |
|---|---|---|
| Valdkond | Farmakoloogia | Farmakoloogia |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 1971 | 1989 |
| Looja≠ | William Chiou and Solomon Riegelman | Ingrid Hidalgo |
| Tüüp≠ | solubility enhancement | absorption screening |
| Algallikas≠ | Chiou, W. L., Riegelman, S. (1971). Pharmaceutical applications of solid dispersions. Journal of Pharmaceutical Sciences, 60(9), 1281-1302. link ↗ | Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749. DOI ↗ |
| Rööpnimetused | solid solution, amorphous dispersion, polymer-based formulation | Caco-2 assay, intestinal permeability, ADME screening |
| Seotud | 3 | 3 |
| Kokkuvõte≠ | Solid dispersion is a formulation technique where a poorly soluble drug is molecularly dispersed in a hydrophilic polymer matrix, improving aqueous solubility and bioavailability. Introduced by Chiou and Riegelman in 1971, solid dispersions remain a key strategy for overcoming solubility-limited absorption. | The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport. |
| ScholarGateAndmestik ↗ |
|
|